CureVac N.V.

NASDAQ:CVAC   3:24:50 PM EDT
39.92
-1.46 (-3.53%)
Products, Regulatory

CureVac Expands CVnCoV Covid-19 Vaccine Candidate Clinical Trial Analyses

Published: 03/22/2021 12:06 GMT
CureVac N.V. (CVAC) - Dgap-news: Curevac Expands Cvncov Covid-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 2b/3 Variant Specification and Efficacy Secondary Endpoint to Phase 2a.
Curevac NV - Impact of New Sars-cov-2 Variants Supports Specification of Select Strains for Anticipated Case-driven Interim Analysis in Pivotal Phase 2b/3 Study.
Curevac NV - Progress in Phase 2a Trial in Older Adults in Peru and Panama Enables Addition of Secondary Vaccine Efficacy Endpoint.
Curevac NV - Curevac Reaffirms Intention to Apply for Formal Market Authorization in Q2 2021.